Overview

Rituximab for Obsessive-compulsive Disorder. (RITS-PO-2019)

Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This study evaluates the addition of rituximab to 12 patients diagnosed with treatment resistant obsessive-compulsive disorder in an open trial.
Phase:
Phase 1
Details
Lead Sponsor:
Region Örebro County
Collaborators:
Örebro University
Örebro University, Sweden
Treatments:
Rituximab